Salubris Biotherapeutics Inc
Clinical trials sponsored by Salubris Biotherapeutics Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New heart failure drug JK07 enters Mid-Stage trial Results expected Oct 2026 (estimated)
-
New heart failure drug JK07 enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests JK07, a lab-made protein designed to help heart cells repair and pump better. About 282 adults with chronic heart failure will receive either JK07 or a placebo. The study looks at safety and whether JK07 can improve heart function in two groups: those wit…
Phase 2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Heart failure drug study pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called JK07 in people with heart failure and a specific type of high blood pressure in the lungs. It planned to enroll about 20 to 30 adults aged 18 to 85. However, the study was withdrawn before any partic…
Phase 2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC